相关实验视频
Updated: Jun 11, 2025

16:11
Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
35.2K
预防性临时右心室辅助装置植入严重双心室性心力衰竭:一个案例系列
Takuma Miyamoto1, Daler Rahimov1, Danial Ahmad1
1Division of Cardiac Surgery, Department of Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.
Artificial organs
|September 30, 2024
概括
在左心室辅助装置 (LVAD) 植入之前,预防性临时右心室辅助装置 (RVAD) 的放置是安全有效的,可以预防右心力衰竭. 这种策略在风险患者中显示了0%的30天死亡率和85.9%的1年生存率.
科学领域:
- 心脏病学 心脏病学
- 心脏外科手术 心脏外科手术
- 机械循环支持 机械循环支持
背景情况:
- 右心室衰竭是左心室辅助器件 (LVAD) 植入后的一个重大并发症.
- 预测和预防性地解决潜在的右心功能障碍对于改善患者的治疗结果至关重要.
研究的目的:
- 评估使用临时右心室辅助装置 (RVAD) 与LVAD植入同时放置的预防性策略的临床结果.
- 评估这种方法在患有右心室衰竭风险的患者中的安全性和有效性.
主要方法:
- 一组患有右心室衰竭风险的患者接受了使用双阶段管 (Protekduo) 的预防性临时RVAD植入.
- 在LVAD植入后,RVAD被连接到氧化器,以促进心肺旁路断奶.
- 在本地麻醉下在床边进行RVAD扩张.
主要成果:
- 十七名患者接受了这种BiVAD (双心辅助装置) 植入技术,平均年龄为55岁,94%是男性.
- 在术后,氧化器在3.5日中位移除,RVAD在8.8日中位移除.
- 该研究报告了0%的30天死亡率和85.9%的1年存活率,尽管术后并发症如延迟胸部关闭 (54.5%) 和急性损伤 (36%).
结论:
- 预防性临时RVAD植入是一种可行的策略,用于管理LVAD后预期的右心力衰竭.
- 这种方法取得了可接受的临床结果,包括出色的短期和长期生存率.
- 该技术为高级心力衰竭管理中的复杂临床挑战提供了安全有效的解决方案.
相关概念视频
Cardiomyopathy V: Interprofessional Care
2
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
2
Cardiomyopathy II: Dilated Cardiomyopathy
1
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
1
Heart Failure VI: Adjunct Therapies
5
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
5
Cardiomyopathy III: Hypertrophic Cardiomyopathy
1
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
1

